Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. - Csizmar CM; Natu A; Gurney M; Fathima S; Alsugair AKA; Kanagal-Shamanna R; Loghavi S; Bazinet A; Chien K; Hammond D; DiNardo C; Kadia T; et al. (Leukemia, 2025)